<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04751084</url>
  </required_header>
  <id_info>
    <org_study_id>2019.109-T</org_study_id>
    <nct_id>NCT04751084</nct_id>
  </id_info>
  <brief_title>Buscopan in Patients Undergoing IVF/Intracytoplasmic Sperm Injection Treatment</brief_title>
  <official_title>Use of Buscopan in Patients Undergoing IVF/Intracytoplasmic Sperm Injection Treatment With High and Low Uterine Contraction Frequency Prior to Embryo Transfer: A Prospective Double-blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if the use of Buscopan in patients undergoing IVF/ICSI treatment with high&#xD;
      uterine contraction frequency prior to embryo transfer has a higher live birth rate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 29, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective double blinded randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>double blinded to the randomization list</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>live birth rate</measure>
    <time_frame>after 24 weeks of gestation</time_frame>
    <description>live baby born</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>implantation rate</measure>
    <time_frame>8-10 days after embryo transfer</time_frame>
    <description>positive pregnancy test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>at 6 weeks gestation</time_frame>
    <description>the presence of at least one gestational sac</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>multiple pregnancy rate</measure>
    <time_frame>after 24 weeks of gestation</time_frame>
    <description>more than 1 live birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miscarriage rate</measure>
    <time_frame>before 24 weeks of gestation</time_frame>
    <description>biochemical if there is no US evidence of pregnancy and clinical if there is US evidence of pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ectopic pregnancy rate</measure>
    <time_frame>at 6-7 weeks of gestation</time_frame>
    <description>IU sac out of uterine cavity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1140</enrollment>
  <condition>IVF</condition>
  <condition>Intracytoplasmic Sperm Injection</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20mg Buscopan intravenous will be given 5 minutes prior to embryo transfer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2ml Normal Saline intravenous will be given 5 minutes prior to embryo transfer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buscopan 20 milligrams/ML Injectable Solution</intervention_name>
    <description>cases will be randomized to Buscopan group or Normal Saline group, injection will be given 5 minutes prior to embryo transfer</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>treatment group</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women undergoing embryo transfer in either fresh or frozen cycles&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Women aged &gt; 42 years old&#xD;
&#xD;
          -  Women with factors which will affect uterine contractility&#xD;
&#xD;
               -  congenital uterine anomaly&#xD;
&#xD;
               -  acquired uterine pathology such as myoma &gt;5cm, adenomyosis &gt;5cm or endometrial&#xD;
                  polyp&#xD;
&#xD;
          -  Women with presence of hydrosalpinx&#xD;
&#xD;
          -  Women undergoing pre-implantation genetic test in IVF cycles&#xD;
&#xD;
          -  History of allergy to misoprostol , Buscopan® or same group of drug&#xD;
&#xD;
          -  Contraindication to the use of Buscopan® e.g. glaucoma, myasthenia gravis,&#xD;
             tachycardia, megacolon&#xD;
&#xD;
          -  Women who are on other smooth muscle relaxant other than Buscopan®&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>aged &lt;42 years old</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sandy Yun Sang Yiu</last_name>
    <phone>3505 1764</phone>
    <email>sandyyiu@cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Yun Sang Yiu</last_name>
      <phone>3505 1764</phone>
      <email>sandyyiu@cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Mak Sze Man Jennifer</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

